Scott Lish Sells 19,900 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 19,900 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $19.64, for a total transaction of $390,836.00. Following the transaction, the chief operating officer owned 641,432 shares of the company’s stock, valued at approximately $12,597,724.48. This represents a 3.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Scott Lish also recently made the following trade(s):

• On Friday, December 5th, Scott Lish sold 10,875 shares of Alphatec stock. The stock was sold at an average price of $21.47, for a total value of $233,486.25.
• On Thursday, November 20th, Scott Lish sold 25,000 shares of Alphatec stock. The shares were sold at an average price of $19.80, for a total value of $495,000.00.

Alphatec Price Performance

Alphatec stock traded up $0.30 during mid-day trading on Thursday, hitting $19.87. 1,203,104 shares of the company were exchanged, compared to its average volume of 2,040,826. Alphatec Holdings, Inc. has a 1-year low of $8.70 and a 1-year high of $22.66. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The business has a fifty day moving average of $18.90 and a 200 day moving average of $15.29. The company has a market capitalization of $2.95 billion, a PE ratio of -19.11 and a beta of 1.08.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The company’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) EPS. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ATEC shares. Needham & Company LLC lifted their price objective on Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Wells Fargo & Company upped their price target on shares of Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Stifel Nicolaus began coverage on shares of Alphatec in a research note on Tuesday, October 28th. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity Group increased their price objective on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Morgan Stanley set a $23.00 target price on shares of Alphatec in a report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in shares of Alphatec during the 3rd quarter worth approximately $74,000. Tudor Investment Corp ET AL increased its stake in shares of Alphatec by 608.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after purchasing an additional 773,367 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Alphatec in the 3rd quarter valued at about $180,000. Oberweis Asset Management Inc. acquired a new stake in Alphatec in the 3rd quarter valued at about $6,705,000. Finally, Dark Forest Capital Management LP grew its holdings in Alphatec by 61.9% during the third quarter. Dark Forest Capital Management LP now owns 120,712 shares of the medical technology company’s stock worth $1,755,000 after purchasing an additional 46,167 shares during the period. Institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.